Number (percent) of medicines categorised according to total number of individuals studied for 6 and 12 mo (long term) prior to marketing.

<p>Percentages presented are row percentages for 6 and 12 mo use. Products with (1) a total number of patients studied of fewer than 1,000, (2) fewer than 300 studied for 6 mo, or (3) fewer than 100 studied for 12 mo do not meet the guideline criteria, and are shown in bold. For purposes of calculation and display, missing data were assumed to be in compliance with the recommended patient exposures.